TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.

doi:10.1016/j.ejca.2021.11.009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.

European journal of cancer (Oxford, England : 1990) - 1 Jan 2022

Thielmann Carl M, Matull Johanna, Zaremba Anne, Murali Rajmohan, Chorti Eleftheria, Lodde Georg, Jansen Philipp, Herbst Rudolf, Terheyden Patrick, Utikal Jochen, Pföhler Claudia, Ulrich Jens, Kreuter Alexander, Mohr Peter, Gutzmer Ralf, Meier Friedegund, Dippel Edgar, Weichenthal Michael, Kretz Julia, Möller Inga, Sucker Antje, Paschen Annette, Livingstone Elisabeth, Zimmer Lisa, Hadaschik Eva, Ugurel Selma, Schadendorf Dirk, Griewank Klaus G

Abstract excerpt

BACKGROUND: Around 50% of cutaneous melanomas harbour therapeutically targetable BRAF V600 mutations. Reliable clinical biomarkers predicting duration of response to BRAF-targeted therapies are still lacking. Recent in vitro studies demonstrated that BRAF-MEK inhibitor therapy response is associated with tumour TERT promoter mutation status. We assessed this potential association in a clinical setting. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Progression-Free Survival

Share to Promoter Regions, Genetic

Share to Proto-Oncogene Proteins B-raf

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 34936949
DOI: 10.1016/j.ejca.2021.11.009
PMCID: PMC9431961

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.PMID 34936949Read ↗

TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis.Semantic proximity Read ↗

TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma PatientsSemantic proximity Read ↗

<scp><i>TERT</i></scp> promoter mutations in melanoma survivalSemantic proximity Read ↗

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In VitroSemantic proximity Read ↗

TERT mutations in Malignant Melanoma-Survival Meta-AnalysisSemantic proximity Read ↗

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.Semantic proximity Read ↗

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.Semantic proximity Read ↗

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases.Semantic proximity Read ↗

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.Semantic proximity Read ↗

TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated MelanomaSemantic proximity Read ↗

TERT promoter mutations associate with fast‐growing melanomaSemantic proximity Read ↗

Clinical and pathological characteristics of familial melanoma with germline TERT promoter variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.